Thermo Fisher third-quarter revenue rises 9% to $12.1 billion

The US scientific equipment and services company reported adjusted earnings of US$6.68 a share, up 15% from a year earlier.

A Thermo Fisher Scientific sign in front of a grey company building in Kamstrup, Denmark
File photo: Thermo Fisher Scientific site in Kamstrup, Denmark (March 2025). Photo: Toxophilus / Wikimedia Commons, CC BY-SA 4.0 (cropped and resized)

Thermo Fisher Scientific reported third-quarter revenue of US$12.14 billion on Wednesday 21 October, up 9% from US$11.12 billion a year earlier. Excluding acquisitions, divestitures and currency effects, organic revenue grew 6%, the company said.

Net income attributable to the company was US$1.72 billion, or US$4.64 a diluted share, up 9% from US$4.27. Adjusted earnings, which exclude items including acquisition-related amortisation and restructuring costs, rose 15% to US$6.68 a share from US$5.79.

Operating margin rose to 18.6% from 17.4%, and the adjusted operating margin was 24.5%, up from 23.3%. Free cash flow was US$2.12 billion in the quarter.

Revenue in its largest segment, Laboratory Products and Biopharma Services, rose to US$6.86 billion from US$5.97 billion. Life Sciences Solutions revenue rose to US$2.72 billion and Analytical Instruments to US$2.00 billion, while Specialty Diagnostics revenue fell to US$1.10 billion from US$1.17 billion.

“We are very pleased to deliver another excellent quarter,” chairman and chief executive Marc Casper said. The company said it completed the sale of its microbiology business during the quarter.

Thermo Fisher, based in Waltham, Massachusetts, said it would give updated 2026 guidance on its earnings call at 11:00am GMT on Wednesday.

Sources

  1. Thermo Fisher Scientific Reports Third Quarter 2026 Results · Thermo Fisher Scientific